SCHEMBL2736791

SCHEMBL2736791

CCCCn1cc(-c2cc3ccccc3s2)cc(C(=O)NCCc2ccccc2)c1=O

nearest known ligand 0.49

Predicted protein targets (top 18)

geneUniProtsupporting neighboursconfidence
CNR2 P34972 4/20 0.49
CNR1 P21554 3/20 0.49
LMNA P02545 4/20 0.46
HTT P42858 2/20 0.46
POLB P06746 1/20 0.46
MAPK1 P28482 1/20 0.46
RAB9A P51151 1/20 0.44
SMN1; SMN2 Q16637 1/20 0.44
GAA P10253 1/20 0.44
MEN1 O00255 1/20 0.43
KMT2A Q03164 1/20 0.43
ALOX15 P16050 5/20 0.42
CD274 Q9NZQ7 1/20 0.41
NPC1 O15118 1/20 0.40
L3MBTL1 Q9Y468 1/20 0.40
ALDH1A1 P00352 1/20 0.40
MAPT P10636 1/20 0.40
HSD17B10 Q99714 1/20 0.40

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL2736790 0.91 CNR2 (0.52) CNR2CNR1LMNAPOLBRAB9A
SCHEMBL2736801 0.85 CNR2 (0.50) CNR2CNR1LMNAHTTPOLB
SCHEMBL2736857 0.84 CNR2 (0.52) CNR2CNR1LMNAHTTPOLB
SCHEMBL2736792 0.84 CNR2 (0.44) CNR2CNR1LMNAHTTPOLB
SCHEMBL2736793 0.83 CD274 (0.57) CNR2CNR1HTTPOLBSMN1; SMN2
SCHEMBL2736853 0.81 LMNA (0.57) CNR2CNR1LMNAHTTPOLB
SCHEMBL2736807 0.81 CNR2 (0.55) CNR2CNR1LMNAHTTPOLB
SCHEMBL2736862 0.81 CNR2 (0.52) CNR2CNR1LMNAHTTPOLB
SCHEMBL2736843 0.81 CNR2 (0.53) CNR2CNR1LMNAHTTPOLB
SCHEMBL2736814 0.81 CNR2 (0.53) CNR2CNR1LMNAHTTPOLB

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 6 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-8088924-B2 Pyridone derivatives having a binding activity to the cannabinoid type 2 receptor SHIONOGI & CO., LTD. (JP) 2012-01-03 US disclosed
US-8088924-B2 Pyridone derivatives having a binding activity to the cannabinoid type 2 receptor SHIONOGI & CO., LTD. (JP) 2012-01-03 US disclosed
US-20100081686-A1 Pyridone derivatives having a binding activity to the cannabinoid type 2 recepter TADA YUKIO 2010-04-01 US disclosed
US-20100081686-A1 Pyridone derivatives having a binding activity to the cannabinoid type 2 recepter TADA YUKIO 2010-04-01 US disclosed
US-7652141-B2 Immunosuppressants, analgesics, antiinflammatory agents SHIONOGI & CO., LTD. (JP) 2010-01-26 US disclosed
US-7652141-B2 Immunosuppressants, analgesics, antiinflammatory agents SHIONOGI & CO., LTD. (JP) 2010-01-26 US disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20100081686-A1 Pyridone derivatives having a binding activity to the cannabinoid type 2 recepter CNR2, CNR1, NPY2R CNR2 1/4885CNR1 2/4885LMNA 3511/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.